ScreenerHero

NUVB Nuvation Bio Inc.

NYSE · US · Healthcare · Biotechnology · nuvationbio.com
4.860USD-0.41%Mkt Cap: 1.71B $P/E: —

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the trea…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap1.71B USD
Enterprise Value1.47B USD
Revenue (TTM)169.90M USD
Gross Profit53.60M USD
Net Income (TTM)-204.63M USD
Revenue/Share0.50 USD
Last Price4.860 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees305
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-325.33
PEG—
EV/EBITDA-10.84
EV/Revenue8.65
P/S10.09
P/B6.72
EPS (TTM)-0.44
EPS (Forward)-0.01
52W Range
3.36023% of range9.750
52W High9.750 USD
52W Low3.360 USD
Profitability
Gross Margin85.22%
Oper. Margin-161.06%
EBITDA Margin-79.74%
Profit Margin-325.31%
ROE-66.93%
ROA-34.40%
Growth
Revenue Growth555.60%
Earnings Growth—
Cash Flow & Leverage
Operating CF-173.43M USD
CapEx (TTM)8.35M USD
FCF Margin-65.99%
FCF Yield-6.57%
Net Debt-244.69M USD
Net Debt/EBITDA1.81
Balance Sheet
Debt/Equity0.19
Current Ratio8.37
Quick Ratio7.98
Book Value/Sh0.73 USD
Cash/Share1.88 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.5 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)13.00 USD
Upside (mean)+167.5%
Target Range7.000 USD – 21.00 USD
7.000+167.5% to mean21.00
# Analysts11
Ownership
Shares Out.350.12M
Float263.65M
Insiders17.19%
Institutions67.60%
Short Interest
Short Ratio11.2d
Short % Float27.28%
Short % Out.16.57%
Shares Short58.17M
Short (prev mo.)53.22M
Technical
SMA 506.317 (-23.1%)
SMA 2005.759 (-15.6%)
Beta1.62
S&P 52W Chg15.78%
Avg Vol (30d)5.14M
Avg Vol (10d)5.89M
Technical Indicators
RSI (14)25.9
MACD-0.3620
MACD Signal-0.2688
MACD Hist.-0.0932
BB Upper6.499 USD
BB Middle5.668 USD
BB Lower4.836 USD
BB Width29.35%
ATR (14)0.2949 USD
Vol Ratio (20d)0.96x